The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: The Jackson Heart Study

European Journal of Preventive Cardiology

Volumn 23, Issue 7, 2016, Pages 769-776

  May, Heidi T ^a   Nelson, John R ^b   Lirette, Seth T ^c   Kulkarni, Krishnaji R ^d   Anderson, Jeffrey L ^a,e   Griswold, Michael E ^c   Horne, Benjamin D ^a,e   Correa, Adolfo ^c   Muhlestein, Joseph B ^a,e  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d Atherotech   (United States)

^e UNIVERSITY OF UTAH   (United States)

Author keywords

apolipoproteins; gender; outcomes; Lipids; lipoprotein ratios; lipoprotein subfractions; remnant lipoproteins; risk

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; APOA1 PROTEIN, HUMAN;

ADULT; ALCOHOL CONSUMPTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONFERENCE PAPER; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; EDUCATIONAL STATUS; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; SMOKING; SYSTOLIC BLOOD PRESSURE; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; ETHNOLOGY; FOLLOW UP; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SEX RATIO; TIME FACTOR; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGE DISTRIBUTION; AGED; APOLIPOPROTEIN A-I; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; TIME FACTORS; UNITED STATES;

EID: 84962384884     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315612733     Document Type: Conference Paper

References (34)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 2012; 127: e6-e245.
2. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
3. May HT, Nelson JR, Kulkarni KR, et al. A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: The apolipoprotein A1 remnant ratio (Apo A1/[VLDL3 + IDL]). Lipids Health Dis 2013; 12: 55-55.
4. Taylor HA Jr, Wilson JG, Jones DW, et al. Toward resolution of cardiovascular health disparities in African Americans: Design and methods of the Jackson Heart Study. Ethn Dis 2005; 15: S6-4-17.
5. Sempos CT, Bild DE, Manolio TA,. Overview of the Jackson Heart Study: A study of cardiovascular diseases in African American men and women. Am J Med Sci 1999; 317: 142-146.
6. Wyatt SB, Diekelmann N, Henderson F, et al. A community-driven model of research participation: The Jackson Heart Study Participant Recruitment and Retention Study. Ethn Dis 2003; 13: 438-455.
7. Kulkarni KR, Garber DW, Marcovina SM, et al. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 1994; 35: 159-168.
8. Kulkarni KR, Tiwari H, Jones SR,. A novel approach to measure apolipoprotein A/apolipoprotein A1 ratio using the Vertical Auto Profile method. Diab Vasc Dis Res 2007; 4: 266-266.
9. Keku E, Rosamond W, Taylor HA Jr, et al. Cardiovascular disease event classification in the Jackson Heart Study: Methods and procedures. Ethn Dis 2005; 15: S6-62-70.
10. Pencina MJ, D'Agostino RB, Zdrojewski T, et al. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol, 22: 1321-1327. DOI: 10.1177/2047487315569411. Epub ahead of print 29 January 2015.
11. Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, Non-HDL-C, and apo B with risk reduction from statin therapy: A meta-analysis of randomized trials. J Am Heart Assoc 2014; 3: e000759-e000759.
12. Sierra-Johnson J, Fisher RM, Romero-Corral A, et al. Concentration on apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-1 ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: Findings from a multi-ethnic US population. Eur Heart J 2009; 30: 710-717.
13. Freedman DS, Strogatz DS, Eaker E, et al. Differences between black and white men in correlates of high density lipoprotein cholesterol. Am J Epidemiol 1990; 132: 656-669.
14. Haffner SM, D'Agostino R Jr, Goff D, et al. LDL size in African Americans, Hispanics, and non-Hispanic whites: The insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 1999; 19: 2234-2240.
15. Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol 1992; 2: 161-176.
16. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-1 and B levels and risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996; 94: 273-278.
17. Gofman JW, Lindgren F,. The role of lipids and lipoproteins in atherosclerosis. Science 1950; 111: 166-171.
18. Mack WJ, Krauss RM, Hodis HN,. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996; 16: 697-704.
19. Krauss RM, Lindgren FT, Williams PT, et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987; 2: 62-66.
20. Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61: 427-436.
21. Varbo A, Benn M, Smith GD, et al. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res 2015; 116: 665-673.
22. Park SY, Lee JH, Kim YK, et al. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther 2005; 312: 1241-1248.
23. Koga H, Sugiyama S, Kugiyama K, et al. Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease. Eur Heart J 2006; 27: 817-823.
24. Fibrinogen Studies Collaboration, Danesh J, Lewington S, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA 2005; 294: 1799-1809.
25. Allison MA, Criqui MH, McClelland RL, et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006; 48: 1190-1197.
26. Tracy RP, Bovill EG, Fried LP, et al. The distribution of coagulation factors VII and VIII and fibrinogen in adults over 65 years. Results from the Cardiovascular Health Study. Ann Epidemiol 1992; 2: 509-519.
27. Varbo A, Benn M, Tybjaerg-Hansen A, et al. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013; 128: 1298-1309.
28. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356: 2388-2398.
29. Ford ES, Giles WH, Dietz WH,. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
30. Bitner V, Johnson BD, Zineh I, et al. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: A Report From the Women's Ischemia Syndrome Evaluation (WISE). Am Heart J 2009; 157: 548-555.
31. Frohlich J, Dobiasova M,. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003; 49: 1873-1880.
32. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial (AMORIS study): A prospective study. Lancet 2001; 358: 2026-2033.
33. Benn M, Nordestgaard BG, Jensen GB, et al. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: The Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007; 27: 661-670.
34. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-951.